Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy-Reference-Cited by-同舟云学术

Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

Published:2022-02-07 Issue:7 Volume:88 Page:3182-3192
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

de Wit Ronald¹,Powles Thomas²,Castellano Daniel³,Necchi Andrea⁴,Lee Jae‐Lyun⁵,van der Heijden Michiel S.⁶,Matsubara Nobuaki⁷,Bamias Aristotelis⁸,Fléchon Aude⁹,Sternberg Cora N.¹⁰,Drakaki Alexandra¹¹,Yu Evan Y.¹²,Zimmermann Annamaria H.¹³,Long Amanda¹³,Walgren Richard A.¹³,Gao Ling¹³,Bell‐McGuinn Katherine M.¹³,Petrylak Daniel P.¹⁴

Affiliation:

1. Erasmus MC Cancer Institute Rotterdam the Netherlands

2. Barts Cancer Institute Queen Mary University of London UK

3. Hospital 12 de Octubre, I + 12 Research Institute Madrid Spain

4. Vita‐Salute San Raffaele University, IRCCS San Raffaele Hospital Milan Italy

5. Asan Medical Centre University of Ulsan College of Medicine Seoul Republic of Korea

6. Netherlands Cancer Institute‐Antoni van Leeuwenhoek Hospital Amsterdam the Netherlands

7. National Cancer Center Hospital East Chiba Japan

8. National and Kapodistrian University of Athens Athens Greece

9. Centre Léon Bérard Lyon France

10. Englander Institute for Precision Medicine Weill Cornell Medicine, Sandra and Edward Meyer Cancer Center New York NY USA

11. University of California Los Angeles Los Angeles CA USA